Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)

NCT06178419 · tracked via the Priya Life Science China tracker

Sponsor

Xuanwu Hospital, Beijing

Phase

Not applicable

Started

2024-01-01

Last updated

2024-09-19

Condition(s) studied

Cerebral IschemiaTakayasu Arteritis

Investigational drug(s) / intervention(s)

RICsham-RIC

RIC: RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.

sham-RIC: Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.

Study summary

The aim of this study is to evaluate the safety and efficacy of remote ischemic conditioning ( RIC ) in the protection of cerebral ischemia in patients with Takayasu arteritis ( TAK ). The study was designed as a prospective, double-blind, exploratory randomized controlled study. The entire study included a screening period and a treatment observation period ( a total of 24 weeks ). All patients with cerebral ischemia of TAK will be randomly divided into RIC group and sham RIC group at 1:1 ratio. On the basis of receiving the conventional drug therapy, the patients will be treated with RIC or sham RIC treatment twice daily for six month. The clinical data of patients at baseline and each follow-up will be collected, including basic information, disease activity assessment, laboratory indicators, imaging indicators, treatment data, adverse events, etc.The Primary outcome is the mean cerebral blood flow improvement rate ( mCBF-IR ) of TAK patients after 24 weeks-treatment. Secondary endpoints include the incidence of major adverse cerebrovascular events ( MACE ) , the change value of arterial transit time ( ATT ) in pCASL hypoperfusion area compared with baseline, occurrence of RIC-related adverse reactions, the changes of hematological indexes and disease activity score, etc. This study will provide insights into the preliminary proof of principle, safety, and efficacy of RIC in cerebral ischemia in patients with Takayasu arteritis ( TAK ), and this data will provide parameters for future larger scale clinical trials if efficacious.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * All patients fulfilled the 1990 American College of Rheumatology Classification Criteria for TAK * Inactive state * Male and female, aged 18-65 years old * The presence of supra-aortic vascular involvement ( including but not limited to the left and right sides of the common carotid artery, subclavian artery, vertebral artery involvement ) * Decreased cerebral blood perfusion in the whole brain ( compared with healthy people ) or local ( left and right brain contrast ) suggested by pseudo-Continuous arterial spin labeling ( pCASL ) -MRI * Voluntary participation in this study, signed informed consent Exclusion Criteria: * Complications that endanger the function of important organs, such as uncontrollable heart failure, severe heart valve disease, severe hypertension, severe myocardial ischemia, pulmonary hypertension, acute cerebral infarction, arterial dissection or aneurysm rupture, etc * There are serious complications, such as poorly controlled diabetes, renal insufficiency, cardiopulmonary insufficiency, mental illness or malignant tumor * There were moderate to severe stenosis of brachial artery in both upper limbs

Primary outcome measure(s)

Mean cerebral blood flow improvement rate — during baseline to 6 months after therapy
Mean cerebral blood flow improvement rate ( mCBF-IR ) of TAK patients will be obtained by pseudo-continuous arterial spin labeling ( pCASL ) -MRI.

Trial sites (1)

Facility	City	Region	Status
Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University, Beijing, China	Beijing	Beijing Municipality	Recruiting

More Xuanwu Hospital, Beijing trials in China

Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease Recruiting

DBS for Treatment-resistant Obsessive-compulsive Disorder Starting soon

The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy Recruiting

Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke Recruiting

Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome Starting soon

Other trials for the same condition

Research on the Application of Sigma Radiopharmaceutical FBFP in Cerebral Stroke Starting soon

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis Recruiting

A Pilot Study in Severe Patients With Takayasu Arteritis. Recruiting

Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy Recruiting

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06178419 on ClinicalTrials.gov ↗ ← All trials in China